Burlingame, CA – According to filings with the U.S. Securities and Exchange Commission, Hinge Bio is raising $19,042,038.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Carin Rollins played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Hinge Bio

Hinge Bio, Inc. is leveraging its proprietary Flex-Hinge antibody platform to develop the next-generation of bispecific and multispecific antibodies that bind with multi-handed cooperativity to both disease targets and effector cells. Hinge Bio’s streamlined chemical ligation process technology enables the production of therapeutic candidates with orders-of-magnitude improved affinity and specificity, incorporating virtually any polypeptide, including gold standard targeting domains such as natural, unmodified Fabs, and effector molecules including agonists, cytokines, growth factors and receptor decoys.

To learn more about Hinge Bio, visit http://hingebio.com/

Contact:
Carin Rollins, Chief Executive Officer
650-488-7070
carin.rollins@hingebio.com
https://www.linkedin.com/in/carin-rollins-243a8337/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved